Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.
The interaction of posaconazole and caspofungin was evaluated in concomitant treatment of Aspergillus fumigatus (two strains) or A. flavus (one strain) systemic infections in immunocompetent mice. Survival curves for mice treated with the combinations were compared statistically with those for mice treated with the component monotherapies. No antagonism was observed.
Cacciapuoti
Anthony
A
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. anthony.cacciapuoti@spcorp.com
Halpern
Judith
J
Mendrick
Cara
C
Norris
Christine
C
Patel
Reena
R
Loebenberg
David
D
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001231:Aspergillus flavus / Q000187:drug effects*; D001232:Aspergillus fumigatus / Q000187:drug effects*; D000077336:Caspofungin; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D054714:Echinocandins; D055666:Lipopeptides; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D014230:Triazoles; C101425:posaconazole; D000077336:Caspofungin